title: Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
abstract: The direct factor Xa (FXa) inhibitors rivaroxaban, apixaban and edoxaban, and the thrombin inhibitor dabigatran etexilate (dabigatran) have gained approval for use in several indications, most notably for the prevention and treatment of venous thromboembolism (VTE) and for the prevention of stroke in patients with atrial fibrillation. Hepatic impairment can affect the disposition of these anticoagulants considerably not only because of the hepatic metabolism of the direct FXa inhibitors but also because moderate to severely impaired hepatic function will affect coagulation. This review describes the key pharmacological properties of novel oral anticoagulants with special attention to patients with impaired hepatic function. In subjects with moderately impaired liver function (i.e. Child-Pugh classification B), the area under the plasma concentration-time curve (AUC) of rivaroxaban (10 mg single dose) is increased by 2.27-fold, which is paralleled by an increase in FXa inhibition. The AUC of apixaban (5 mg single dose) is increased by 1.09-fold, whereas the AUC of edoxaban (15 mg single dose) is decreased by 4.8 % and the AUC of dabigatran (150 mg single dose) is decreased by 5.6 %. Specific labelling restrictions for rivaroxaban, apixaban and dabigatran regarding impaired hepatic function are based on both the Child-Pugh classification and liver-related exclusion criteria applied in pivotal clinical trials. Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients classified as Child-Pugh B and C. Apixaban can be used with caution in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment or in patients with alanine aminotransferase and aspartate aminotransferase levels >2× upper limit of normal (ULN). Apixaban is not recommended in patients with severe hepatic impairment and is contraindicated in those with hepatic disease associated with coagulopathy and clinically relevant bleeding risk. Dabigatran is not recommended in patients with elevated liver enzymes (>2× ULN). Dabigatran is contraindicated in patients with hepatic impairment or liver disease expected to have any impact on survival. Currently, edoxaban is not available in the US or European markets. However, the Japanese label did not restrict use in hepatic dysfunction but advises care in patients with severe hepatic impairment.
authors: pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
authors: Jochen
authors: J
authors: Graff
authors: Sebastian
authors: S
authors: Harder
mesh_terms: D000042:Absorption; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D006801:Humans; D008107:Liver Diseases / Q000150:complications* / Q000378:metabolism; D008657:Metabolic Clearance Rate; D009025:Morpholines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D011728:Pyridones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069552:Rivaroxaban; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014018:Tissue Distribution; D054556:Venous Thromboembolism / Q000097:blood / Q000150:complications / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; D013917:Thrombin; D000069604:Dabigatran; C552171:edoxaban
references: J Clin Pharmacol. 2007 Feb;47(2):218-26
references: 17244773
references: Hepatology. 2001 Dec;34(6):1103-8
references: 11731998
references: Clin Pharmacokinet. 2009;48(1):1-22
references: 19071881
references: Drug Metab Dispos. 2008 Feb;36(2):386-99
references: 18006647
references: Clin Pharmacokinet. 2005;44(2):187-200
references: 15656697
references: Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):129-39
references: 21461793
references: J Thromb Haemost. 2005 Mar;3(3):514-21
references: 15748242
references: BMC Fam Pract. 2012 Feb 03;13:5
references: 22304704
references: Thromb Haemost. 2011 Mar;105(3):444-53
references: 21136019
references: Adv Ther. 2012 Mar;29(3):187-201
references: 22354465
references: Br J Clin Pharmacol. 2007 Sep;64(3):292-303
references: 17506785
references: Am J Geriatr Pharmacother. 2012 Apr;10(2):160-3
references: 22386824
references: Drug Metab Dispos. 2011 Feb;39(2):256-64
references: 21071521
references: Ann Pharmacother. 2012 Apr;46(4):e10
references: 22496474
references: Semin Liver Dis. 2002 Feb;22(1):83-96
references: 11928081
references: News Physiol Sci. 1999 Jun;14:117-121
references: 11390834
references: Am J Health Syst Pharm. 2007 Apr 1;64(7):690, 692-3
references: 17384352
references: N Engl J Med. 2010 Dec 23;363(26):2499-510
references: 21128814
references: J Clin Pharmacol. 2012 Jul;52(7):964-75
references: 21610202
references: Chest. 2008 Jun;133(6 Suppl):234S-256S
references: 18574267
references: Circulation. 2011 Oct 4;124(14):1573-9
references: 21900088
references: Lancet. 2007 Sep 15;370(9591):949-56
references: 17869635
references: Clin Chem. 2002 Jun;48(6 Pt 1):850-8
references: 12029000
references: Clin Chem Lab Med. 2011 May;49(5):761-72
references: 21288169
references: Hepatology. 2005 Mar;41(3):553-8
references: 15726661
references: Br J Clin Pharmacol. 2013 Jul;76(1):89-98
references: 23294275
references: Postgrad Med J. 2008 Apr;84(990):177-81
references: 18424573
references: Curr Drug Metab. 2004 Apr;5(2):157-67
references: 15078193
references: Eur J Clin Pharmacol. 2005 Dec;61(12):873-80
references: 16328318
references: Clin Pharmacokinet. 2010 Apr;49(4):259-68
references: 20214409
references: N Engl J Med. 2011 Mar 3;364(9):806-17
references: 21309657
references: Best Pract Res Clin Gastroenterol. 2001 Dec;15(6):897-918
references: 11866484
references: Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32
references: 391462
references: N Engl J Med. 2009 Aug 6;361(6):594-604
references: 19657123
references: Adv Ther. 2010 Sep;27(9):623-33
references: 20680533
references: Drug Metab Dispos. 2009 May;37(5):1056-64
references: 19196845
references: N Engl J Med. 2011 Sep 15;365(11):981-92
references: 21870978
references: Annu Rev Med. 2011;62:41-57
references: 21226611
references: Clin Pharmacol Ther. 2006 Sep;80(3):235-45
references: 16952490
references: Hepatology. 2006 Oct;44(4):1039-46
references: 17006940
references: Br J Haematol. 2010 Feb;148(4):507-21
references: 19995396
references: N Engl J Med. 2010 Dec 23;363(26):2487-98
references: 21175312
references: Br J Clin Pharmacol. 2010 Nov;70(5):703-12
references: 21039764
references: Drugs. 2011 Aug 20;71(12):1503-26
references: 21861537
references: J Pharmacol Exp Ther. 2011 Jul;338(1):372-80
references: 21515813
references: Clin Pharmacokinet. 1995 Nov;29(5):370-91
references: 8582120
references: J Thromb Haemost. 2007 Apr;5(4):886-8
references: 17388799
references: N Engl J Med. 2011 Jul 14;365(2):147-56
references: 21751907
references: Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):640-50
references: 21593017
references: Drug Saf. 2005;28(6):529-45
references: 15924505
references: Br J Surg. 1973 Aug;60(8):646-9
references: 4541913
references: Circulation. 2011 Apr 5;123(13):1436-50
references: 21464059
references: Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9
references: 20671233
references: Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):376-81
references: 20139357
references: N Engl J Med. 2012 Apr 5;366(14):1287-97
references: 22449293
references: Thromb Haemost. 2010 Mar;103(3):572-85
references: 20135071
references: Discov Med. 2012 Jun;13(73):445-50
references: 22742650
references: Xenobiotica. 2005 Sep;35(9):891-910
references: 16308283
references: Thromb Haemost. 2011 Apr;105(4):721-9
references: 21225098
references: Drug Metab Dispos. 2009 Jan;37(1):74-81
references: 18832478
references: Thromb Haemost. 2007 Oct;98(4):756-64
references: 17938798
references: N Engl J Med. 2011 Sep 8;365(10):883-91
references: 21830957
references: Clin Pharmacokinet. 2008;47(1):47-59
references: 18076218
references: N Engl J Med. 2009 Sep 17;361(12):1139-51
references: 19717844
references: Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
references: 16305721
references: J Thromb Haemost. 2008 May;6(5):820-9
references: 18315548
references: Clin Pharmacol Ther. 2005 Oct;78(4):412-21
references: 16198660
references: Gastroenterology. 2003 Jan;124(1):91-6
references: 12512033
references: Am J Hematol. 2012 May;87 Suppl 1:S141-5
references: 22473649
references: J Clin Pharmacol. 2008 Dec;48(12):1411-9
references: 18827075